EUVIMEDScopri EUVIMED
Open access · CC BY-NC-ND 4.0

HPV vaccination following cervical intraepithelial neoplasia grade 2 diagnosis and risk of progression

Dina O Eriksen iD, Louise Krog iD, Eva B Ostenfeld, Pernille T Jensen, Kathrine D Lycke, Therese K Grønborg, Nicolas Wentzensen, Megan A Clarke, Anne Hammer iD

Acta Obstetricia et Gynecologica Scandinavica · 2026

DOI: 10.1111/aogs.70128 ↗

At a glance

Journal article in Acta Obstetricia et Gynecologica Scandinavica, 2026. Written by Dina O Eriksen and 8 co-authors. Institution: University Clinic for Gynecological HPV-Related Disease, Department of Obstetrics and Gynecology, Gødstrup Hospital, Herning, Denmark. Major MEDLINE topics: Uterine Cervical Dysplasia, Papillomavirus Vaccines, Uterine Cervical Neoplasms, Papillomavirus Infections. Cited 3 times so far (Crossref); 27 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Kræftens Bekæmpelse, Dansk Kræftforsknings Fond, Research Fund at Regional Hospital Gødstrup.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Introduction

Human papillomavirus (HPV) vaccination is associated with a significantly reduced risk of cervical cancer when administered before initial exposure to HPV. Women with high‐grade cervical intraepithelial neoplasia (CIN) have an increased risk of subsequent HPV‐related disease, including recurrent high‐grade CIN, compared to women without CIN. Some clinicians have advised women with high‐grade CIN to undergo HPV vaccination to reduce their subsequent risk, despite a lack of evidence for this practice. We aimed to evaluate whether HPV vaccination of women undergoing active surveillance for CIN grade 2 (CIN2) is associated with a decreased risk of progression to cervical intraepithelial neoplasia grade 3 or worse (CIN3+). Material and Methods We conducted a nationwide population‐based historical cohort study in Denmark on women aged 18–40 years undergoing active surveillance for CIN2 from 2007 to 2020. We compared women receiving at least one HPV vaccine dose within 6 months after their CIN2 diagnosis to women not receiving the vaccine. Our primary outcome was progression to CIN3+. We stratified by age at CIN2 diagnosis (18–29, 30–40), calendar year (2007–2012, 2013–2020), and index cytology (high‐grade, nonhigh‐grade). We used Cox proportional hazards regression to estimate hazard ratios of the outcomes with unvaccinated women as the reference. Age at diagnosis, calendar year, index cytology, income, and educational level were adjusted for.

Results

We included 4585 women, of whom 583 (12.7%) were vaccinated within 6 months after CIN2 diagnosis. A total of 1391 (30.3%) progressed to CIN3+ during follow‐up. The 5‐year cumulative risk was 29.9% (28.5–31.3). Overall, no protective effect of vaccination after CIN2 diagnosis was found (aHR 1.45 [1.24–1.69]). Stratified analyses showed increased progression risk with vaccination among women

Subjects

MeSH terms (MEDLINE)

Uterine Cervical DysplasiaPapillomavirus VaccinesUterine Cervical NeoplasmsPapillomavirus InfectionsVaccinationHumansFemaleAdultDisease ProgressionDenmarkYoung AdultAdolescentCohort StudiesNeoplasm Grading

Author keywords

HPV vaccinationcervical cancer screeningcervical intraepithelial neoplasiaepidemiology

Substances

Papillomavirus Vaccines

Authors and institutions

  • University Clinic for Gynecological HPV-Related Disease, Department of Obstetrics and Gynecology, Gødstrup Hospital, Herning, Denmark.
  • Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • NIDO | Centre for Research and Education, Gødstrup Hospital, Herning, Denmark.
  • Department of Obstetrics and Gynecology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
  • Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.

ORCID profiles: Dina O Eriksen, Louise Krog, Anne Hammer

Funding

  • Kræftens Bekæmpelse
  • Dansk Kræftforsknings Fond
  • Research Fund at Regional Hospital Gødstrup

Cite

APA

Eriksen, D. O., Krog, L., Ostenfeld, E. B., Jensen, P. T., Lycke, K. D., Grønborg, T. K., Wentzensen, N., Clarke, M. A., & Hammer, A. (2026). HPV vaccination following cervical intraepithelial neoplasia grade 2 diagnosis and risk of progression. Acta Obstetricia et Gynecologica Scandinavica. https://doi.org/10.1111/aogs.70128

Vancouver

Eriksen DO, Krog L, Ostenfeld EB, Jensen PT, Lycke KD, Grønborg TK, et al. HPV vaccination following cervical intraepithelial neoplasia grade 2 diagnosis and risk of progression. Acta Obstetricia et Gynecologica Scandinavica. 2026. doi:10.1111/aogs.70128

BibTeX
@article{Eriksen2026,
  author = {Eriksen, Dina O and Krog, Louise and Ostenfeld, Eva B and Jensen, Pernille T and Lycke, Kathrine D and Grønborg, Therese K and Wentzensen, Nicolas and Clarke, Megan A and Hammer, Anne},
  title = {HPV vaccination following cervical intraepithelial neoplasia grade 2 diagnosis and risk of progression},
  journal = {Acta Obstetricia et Gynecologica Scandinavica},
  year = {2026},
  doi = {10.1111/aogs.70128}
}
Start for free →